Hims & Hers Health (NYSE:HIMS) Price Target Raised to $23.00 at Jefferies Financial Group

Hims & Hers Health (NYSE:HIMS) had its price objective boosted by Jefferies Financial Group from $14.00 to $23.00 in a report issued on Thursday morning, Benzinga reports. Jefferies Financial Group currently has a hold rating on the stock.

Other equities research analysts have also issued reports about the company. Citigroup lowered Hims & Hers Health from a buy rating to a neutral rating and upped their price target for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $14.00 to $16.00 and gave the stock a hold rating in a research report on Tuesday, May 7th. Bank of America boosted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a buy rating in a research report on Thursday, June 13th. TheStreet raised shares of Hims & Hers Health from a d rating to a c rating in a report on Monday, March 4th. Finally, Canaccord Genuity Group assumed coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a buy rating and a $20.00 target price for the company. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of Moderate Buy and an average target price of $17.00.

Hims & Hers Health Price Performance

NYSE HIMS opened at $20.01 on Thursday. The company has a market capitalization of $4.30 billion, a price-to-earnings ratio of -2,001.00 and a beta of 1.08. Hims & Hers Health has a 12 month low of $5.65 and a 12 month high of $25.74. The company’s fifty day moving average price is $17.42 and its two-hundred day moving average price is $13.41.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.05) earnings per share. As a group, analysts anticipate that Hims & Hers Health will post 0.19 EPS for the current year.

Insider Activity

In related news, insider Soleil Boughton sold 2,503 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $15.65, for a total value of $39,171.95. Following the completion of the transaction, the insider now owns 166,866 shares in the company, valued at approximately $2,611,452.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Oluyemi Okupe sold 11,546 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $22.21, for a total value of $256,436.66. Following the completion of the sale, the chief financial officer now owns 177,449 shares in the company, valued at $3,941,142.29. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the transaction, the insider now directly owns 166,866 shares in the company, valued at $2,611,452.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 962,791 shares of company stock valued at $16,930,725. Company insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in the business. Belpointe Asset Management LLC lifted its stake in Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Hims & Hers Health by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock valued at $261,000 after acquiring an additional 1,561 shares during the last quarter. Swiss National Bank boosted its stake in shares of Hims & Hers Health by 0.7% during the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after acquiring an additional 2,000 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Hims & Hers Health by 10.0% in the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock worth $344,000 after acquiring an additional 2,023 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Hims & Hers Health by 17.9% during the first quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock worth $258,000 after purchasing an additional 2,525 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.